Impact of Ceftazidime Use on Susceptibility Patterns in a Neonatal Intensive Care Unit: A 7.5-year Evaluation

J Pediatric Infect Dis Soc. 2022 Jul 21;11(7):349-350. doi: 10.1093/jpids/piac019.

Authors

Rebecca A Mayes¹, Peter N Johnson², Bryan P White¹, Stephen B Neely³, Hala Chaaban⁴, Jamie L Miller²

Affiliations

¹ Department of Pharmacy, OU Health, Oklahoma City, Oklahoma, USA.
² Department of Pharmacy: Clinical and Administrative Sciences, University of Oklahoma College of Pharmacy, Oklahoma City, Oklahoma, USA.
³ Department of Pharmacy, University of Oklahoma College of Pharmacy, Oklahoma City, Oklahoma, USA.
⁴ Department of Pediatrics, University of Oklahoma College of Medicine, Oklahoma City, Oklahoma, USA.

PMID: 35390154
DOI: 10.1093/jpids/piac019

No abstract available

MeSH terms

Anti-Bacterial Agents / therapeutic use
Ceftazidime* / therapeutic use
Gram-Negative Bacteria
Humans
Infant, Newborn
Intensive Care Units, Neonatal*
Microbial Sensitivity Tests

Substances

Anti-Bacterial Agents
Ceftazidime